7,580.25

+5.75

+0.08%

52,011.00

-122.00

-0.23%

28,246.00

+118.50

+0.42%

Russell 2000 Futures

2,819.60

+1.80

+0.06%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,953.10

-16.50

-0.42%

76,831.27

-1,502.95

-1.92%

Crude Oil Dec 26

96.24

-0.22

-0.23%

US Private Equity

10,836.30

-14.33

-0.13%

Copenhagen - Delayed Quote DKK

BioPorto A/S (BIOPOR.CO)

1.0100 -0.0100 (-0.98%)

At close: November 2 at 4:59:48 PM GMT+1

First Patient In - BioPorto Initiates Patient Enrollment as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

GlobeNewswire 1mo ago

BIOPOR.CO
-0.98%
BioPorto announces Interim Results for the Second Quarter and First half of 2026

GlobeNewswire 2mo ago

BIOPOR.CO
-0.98%
BioPorto activates the first US clinical site as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

GlobeNewswire 2mo ago

BIOPOR.CO
-0.98%
Grant of Warrants

GlobeNewswire 4mo ago

BIOPOR.CO
-0.98%
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

GlobeNewswire 4mo ago

BIOPOR.CO
-0.98%
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026

GlobeNewswire 5mo ago

BIOPOR.CO
-0.98%
Resolutions of the Annual General Meeting

GlobeNewswire 6mo ago

BIOPOR.CO
-0.98%
Major Shareholder Announcement

GlobeNewswire 6mo ago

BIOPOR.CO
-0.98%
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis

GlobeNewswire 6mo ago

BIOPOR.CO
-0.98%
KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease

GlobeNewswire 6mo ago

BIOPOR.CO
-0.98%
BioPorto announces the Annual Report for 2025

GlobeNewswire 7mo ago

BIOPOR.CO
-0.98%
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7

GlobeNewswire 1mo ago

BIOPOR.CO
-0.98%

Mobilize your Website

View Site in Mobile | Classic

Share by: